FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386916072> ?p ?o ?g. }

• W4386916072 abstract "There are currently no standard therapy regimens for the third-line treatment of metastatic pancreatic cancer (mPC) patients. The aim of the present study was to compare the efficacy and safety of different third-line therapy regimens for mPC in the real-world.This study retrospectively analyzed mPC patients admitted to Zhejiang Provincial People's Hospital between June 2013 and January 2023. All patients' diagnoses were pathologically confirmed and their treatment was continued after the second-line therapy failed. The primary study endpoints included median overall survival (mOS), median progression-free survival (mPFS), and disease control rate (DCR).A total of 72 patients were enrolled in the study. Of these, 36 patients received chemotherapy alone, 16 received chemotherapy combined with targeted therapy or immunotherapy, 14 received chemotherapy-free antitumor therapy, and six received palliative care. The mPFS value for these groups was 4.40 months, 5.20 months, 2.33 months, and 0.80 months, respectively. The mOS value was 6.90 months, 5.90 months, 3.33 months, and 0.80 months, respectively. The DCR was 33.4%, 31.3%, 21.4%, and 0.0%, respectively. Overall, there were significant differences in prognosis between the palliative care group and the other treatment groups (mOS, P < 0.001; mPFS P < 0.001; DCR, P < 0.001). The differences among the mPFS, mOS, and DCR for different antitumor therapy regimens were not statistically significant. Compared to the chemotherapy alone group, the chemotherapy combined with targeted therapy or immunotherapy group experienced more adverse events (100% vs. 75.0%; P = 0.002). Chemotherapy combined with targeted therapy or immunotherapy was associated with a higher risk of grade 3/4 hyperaminotransferemia compared to chemotherapy alone (31.3% vs. 0.0%; P = 0.020) and chemotherapy-free antitumor therapy (31.3% vs. 0.0%; P = 0.020).Third-line antitumor therapy can prolong the survival time of patients with mPC. Targeted therapy or immunotherapy failed to further improve survival benefits based on chemotherapy results. Patients who underwent the third-line treatment with good physical status and family history of cancer were independent prognostic factors for longer mOS. The sequencing of fluorouracil and gemcitabine in the front-line therapy did not affect third-line mOS." @default.
• W4386916072 created "2023-09-22" @default.
• W4386916072 creator A5010111611 @default.
• W4386916072 creator A5021464011 @default.
• W4386916072 creator A5026501857 @default.
• W4386916072 creator A5019393531 @default.
• W4386916072 creator A5086664449 @default.
• W4386916072 date "2023-09-21" @default.
• W4386916072 modified "2023-10-10" @default.
• W4386916072 title "Third-line treatment options in metastatic pancreatic cancer patients: a real-world study" @default.
• W4386916072 cites W1264670492 @default.
• W4386916072 cites W2151253787 @default.
• W4386916072 cites W2165480504 @default.
• W4386916072 cites W2187917981 @default.
• W4386916072 cites W2472707660 @default.
• W4386916072 cites W2610989131 @default.
• W4386916072 cites W2775876340 @default.
• W4386916072 cites W2790254562 @default.
• W4386916072 cites W2800389517 @default.
• W4386916072 cites W2803262426 @default.
• W4386916072 cites W2921145883 @default.
• W4386916072 cites W2984359187 @default.
• W4386916072 cites W2996168784 @default.
• W4386916072 cites W2996574710 @default.
• W4386916072 cites W2998609748 @default.
• W4386916072 cites W3004985558 @default.
• W4386916072 cites W3087213110 @default.
• W4386916072 cites W3087232085 @default.
• W4386916072 cites W3127664533 @default.
• W4386916072 cites W3130714601 @default.
• W4386916072 cites W3132199378 @default.
• W4386916072 cites W3153075376 @default.
• W4386916072 cites W4234647115 @default.
• W4386916072 cites W4240742313 @default.
• W4386916072 cites W4243514481 @default.
• W4386916072 cites W4285058973 @default.
• W4386916072 cites W4293439579 @default.
• W4386916072 doi "https://doi.org/10.3389/fonc.2023.1251258" @default.
• W4386916072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37810973" @default.
• W4386916072 hasPublicationYear "2023" @default.
• W4386916072 type Work @default.
• W4386916072 citedByCount "0" @default.
• W4386916072 crossrefType "journal-article" @default.
• W4386916072 hasAuthorship W4386916072A5010111611 @default.
• W4386916072 hasAuthorship W4386916072A5019393531 @default.
• W4386916072 hasAuthorship W4386916072A5021464011 @default.
• W4386916072 hasAuthorship W4386916072A5026501857 @default.
• W4386916072 hasAuthorship W4386916072A5086664449 @default.
• W4386916072 hasBestOaLocation W43869160721 @default.
• W4386916072 hasConcept C121608353 @default.
• W4386916072 hasConcept C126322002 @default.
• W4386916072 hasConcept C141071460 @default.
• W4386916072 hasConcept C143998085 @default.
• W4386916072 hasConcept C197934379 @default.
• W4386916072 hasConcept C2776694085 @default.
• W4386916072 hasConcept C2777701055 @default.
• W4386916072 hasConcept C2780210213 @default.
• W4386916072 hasConcept C71924100 @default.
• W4386916072 hasConceptScore W4386916072C121608353 @default.
• W4386916072 hasConceptScore W4386916072C126322002 @default.
• W4386916072 hasConceptScore W4386916072C141071460 @default.
• W4386916072 hasConceptScore W4386916072C143998085 @default.
• W4386916072 hasConceptScore W4386916072C197934379 @default.
• W4386916072 hasConceptScore W4386916072C2776694085 @default.
• W4386916072 hasConceptScore W4386916072C2777701055 @default.
• W4386916072 hasConceptScore W4386916072C2780210213 @default.
• W4386916072 hasConceptScore W4386916072C71924100 @default.
• W4386916072 hasLocation W43869160721 @default.
• W4386916072 hasLocation W43869160722 @default.
• W4386916072 hasOpenAccess W4386916072 @default.
• W4386916072 hasPrimaryLocation W43869160721 @default.
• W4386916072 hasRelatedWork W2012081960 @default.
• W4386916072 hasRelatedWork W2072687151 @default.
• W4386916072 hasRelatedWork W2079105677 @default.
• W4386916072 hasRelatedWork W2263008850 @default.
• W4386916072 hasRelatedWork W2348276370 @default.
• W4386916072 hasRelatedWork W2971868466 @default.
• W4386916072 hasRelatedWork W3028147324 @default.
• W4386916072 hasRelatedWork W3160432000 @default.
• W4386916072 hasRelatedWork W4221015902 @default.
• W4386916072 hasRelatedWork W4285034957 @default.
• W4386916072 hasVolume "13" @default.
• W4386916072 isParatext "false" @default.
• W4386916072 isRetracted "false" @default.
• W4386916072 workType "article" @default.